CKD Bio종근당바이오
063160 · KOSPI · ₩063160 · 종근당바이오
₩12,380▲ ₩280 (2.31%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩160B | ₩172B | ₩160B | ₩156B | ₩142B |
| Cost of sales | ₩131B | ₩136B | ₩152B | ₩138B | ₩129B |
| Gross profit | ₩29B | ₩36B | ₩8B | ₩18B | ₩13B |
| Operating income | ₩3.6B | ₩11B | −₩20B | −₩13B | −₩8.8B |
| Net income | −₩2.9B | ₩8.7B | −₩24B | −₩15B | −₩10B |
| Net income to shareholders | −₩2.9B | ₩8.7B | −₩24B | −₩15B | −₩10B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩300B | ₩284B | ₩294B | ₩312B | ₩297B |
| Current assets | ₩136B | ₩115B | ₩112B | ₩123B | ₩103B |
| Cash and equivalents | ₩1.4B | ₩1.1B | ₩3.6B | ₩4.7B | ₩2.8B |
| Total liabilities | ₩173B | ₩153B | ₩171B | ₩165B | ₩137B |
| Current liabilities | ₩152B | ₩91B | ₩99B | ₩81B | ₩44B |
| Borrowings | ₩143B | ₩130B | ₩145B | ₩137B | ₩106B |
| Total equity | ₩127B | ₩131B | ₩123B | ₩148B | ₩160B |
| Shareholders' equity | ₩127B | ₩131B | ₩123B | ₩148B | ₩160B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩4.1B | ₩14B | −₩7.2B | −₩2.5B | −₩3.3B |
| Capital spending | ₩6.8B | ₩3.4B | ₩7.6B | ₩6.2B | ₩20B |
| Free cash flow | −₩11B | ₩11B | −₩15B | −₩8.7B | −₩24B |
| Dividends paid | ₩549M | ₩0 | ₩0 | ₩549M | ₩1.1B |
Consolidated where available. Amounts in won.
Also known as: CKD Bio / 종근당바이오 / 063160 / KRX:063160
Source: KRX statistical information